Myocardial Ischemia Biomarker H-FABP Used to Diagnose Acute Coronary Syndrome

 

June 20, 2011
Randox Laboratories' automated laboratory assay for heart-type fatty acid binding protein (H-FABP) is designed to improve the diagnosis and management of patients with suspected acute coronary syndrome (ACS).

This rapid, fully quantitative assay means that H-FABP can be used routinely in the acute clinical setting; previous laboratory assays were more suited to research.

Trials have shown that H-FABP provides significant diagnostic value, especially during the early hours following ACS symptom onset. Such results are particularly valuable in the early period when current diagnostics struggle and many patients are conservatively admitted for observation, often unnecessarily. The use of H-FABP, alongside troponin, offers the potential to rule out ACS in many patients from the time of presentation.

These results have also been shown to apply to "high sensitivity" troponins (hsTn). The outcomes of one study from the University of Manchester, U.K., suggest that a combination hsTn, H-FABP and electrocardiogram (ECG) on admission will provide a highly accurate test for AMI.

For more information: www.randox.com